Private Placement

With a new capital markets heavyweight on its board, Silver Viper Minerals signals a major push to advance its growing portfolio of precious metals projects.

With major clinical trials, including a novel approach for Alzheimer's, and key market access wins, MMI's Symani system is poised to redefine microsurgery.

Facing cautious investors, Silicom bets its future on next-gen tech like PQC and Edge. Can its bold growth plans overcome recent financial turbulence?

With its first drug for a rare disease now on the market, Stealth BioTherapeutics bets its future on a deep pipeline targeting mitochondrial dysfunction.

From e-commerce to tech licensor, Linkage Global unveils smart headphones with AI translation and cultural heritage designs at CES 2026.

Early trial data for IKS014 reveals a high clinical benefit rate in pre-treated oesophageal cancer, offering a new beacon of hope for a hard-to-treat disease.

Iron Software funds biochar kilns in Chiang Mai, tackling an environmental crisis that threatens the city's 'mini Silicon Valley' status.

Menlo Ventures promotes General Counsel Deborah Carrillo to Partner, a move reflecting a crucial industry shift where legal expertise is now a core strategic asset.

Inspira Technologies announces a landmark deal to acquire a liquid biopsy firm, securing a $15M investment at a $180M valuation to enter the cancer market.

The acclaimed '1/6' graphic novel series releases its finale, a resistance-driven story that eerily anticipated authoritarian moves in a post-Jan. 6 world.

Processa Pharmaceuticals completes enrollment for a pivotal analysis of its NGC-Cap therapy, offering new hope for a safer, more effective cancer treatment.

At CES 2026, Ubicept's new toolkit promises to let AI see clearly in the dark and at high speed, ushering in a new era for robotics and autonomous cars.

With surging revenue for its cholesterol drugs and new guideline backing, Esperion outlines its strategy for profitability and pipeline expansion.

With stunning clinical data for its miv-cel therapy, Kyverna is set to outline a new era for autoimmune treatment at the J.P. Morgan conference.

With blockbuster sales from VYJUVEK, Krystal Biotech heads to J.P. Morgan with investors eager for news on its global growth and ambitious pipeline.

A new therapy claims to reverse cellular aging to cure disease, but its patient-funded trial model sparks a debate on equity and medical ethics.

Circle Pharma will unveil its pipeline of novel oral macrocycle drugs targeting elusive cancer drivers at the influential J.P. Morgan Healthcare Conference.

With promising 3-year vision data and a manufacturing breakthrough, Lineage is pioneering 'off-the-shelf' cell therapies for blindness, diabetes, and more.

A landmark $1.2M order for its advanced LineaDNA validates the firm's biotech arm, but can scientific success balance its new, volatile crypto strategy?

A new 10,000-sample 'skin library' collected by painless stickers aims to slash drug development time and costs for biopharmaceutical partners.